Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Flow Cytometric Assay Evaluated for Heparin-Induced Thrombocytopenia

By LabMedica International staff writers
Posted on 05 Jul 2016
Heparin-induced thrombocytopenia (HIT) is an immune-mediated thrombocytopenia associated with heparin therapy and the diagnosis consists of a combination of pretest probability and laboratory testing.

The routinely available laboratory antigen binding assays for the detection of specific antibodies have a low HIT-positive predictive value; therefore, to exclude false-positive results, one of the functional assays should be performed. More...
Functional assays evaluate the ability of heparin/platelet factor 4 (PF4) antibodies to activate the platelets.

Scientists at the University Medical Centre Ljubljana (Slovenia) investigated sera from adult patients, in which HIT was suspected, for the presence of HIT antibodies, using an immunoglobulin G enzyme-linked immunosorbent assay (IgG-ELISA) as the laboratory standard practice. After they set up the functional assay, 41 ELISA-positive serum samples were collected randomly for further testing.

The team tested the sera using an IgG-specific ELISA Kit (GTI Diagnostics, Inc., Waukesha, WI, USA). Platelet-activating antibodies were detected with a functional flow cytometric assay and analyzed on a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). A functional heparin-induced platelet aggregation assay (HIPA) was also performed. Each test included diluted serum from the HIT patients as weak positive controls and serum from healthy donors as negative controls. To set up the cutoff of the flow cytometric assay, they analyzed a total of 100 samples, 25 HIT-positive and HIT-negative sera, each tested with different donor platelets.

The scientists found that of 41 ELISA positive serum samples, 14 were positive and 20 were negative by both flow cytometer and HIPA. Three other samples were discrepant between two assays: they were HIPA-positive and were negative with the flow cytometric assay. Conversely, four samples were flow cytometer positive and HIPA-negative. The samples included in this comparison were sera with detected anti-heparin/PF4 IgG antibodies with an OD greater than 0.4. The diagnostic specificity of the flow cytometric assay was calculated based on HIPA results and was 83%.

The authors concluded that performing this functional test after the screening assay could significantly improve the specificity of HIT testing as heparin/PF4 antibodies are often not clinically significant. The study was published in the June 2016 edition of the International Journal of Laboratory Hematology.

Related Links:
University Medical Centre Ljubljana
GTI Diagnostics
Becton Dickinson

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.